See the DrugPatentWatch profile for Mefenamic
What’s the global mefenamic acid market like (size, growth, and demand drivers)?
I don’t have any market-size, forecast, or geography-specific figures in the provided information, so I can’t state the current market value or growth rate reliably.
What I can say generally is that the mefenamic acid market is driven by demand for nonsteroidal anti-inflammatory drugs (NSAIDs) used for pain and inflammation, including menstrual (period) pain, and by factors that typically affect NSAID sales such as:
- availability in different countries (brand/generic access)
- regulator approval status and prescribing patterns
- competition from other NSAIDs (ibuprofen, naproxen, diclofenac) and alternative therapies
If you share whether you mean “global market” vs “US/EU/India/China,” and whether you want forecasts (2024–2030, etc.), I can tailor the answer around that.
Where is mefenamic acid used the most?
Mefenamic acid is primarily sold for treatment of pain and inflammation, with a common indication being dysmenorrhea (menstrual cramps). It’s also used for other types of pain where NSAIDs are appropriate, depending on local labeling and clinician practice.
Who typically sells mefenamic acid (brands vs generics)?
Mefenamic acid is widely available as a generic in many markets, usually in tablet form. Brand competition varies by country, but generic manufacturers tend to dominate pricing and volume in most places.
If you tell me the country/region you care about, I can narrow down the likely brand landscape and distribution model.
Is the market affected by patents or exclusivity?
Mefenamic acid is an older active ingredient, so the market is usually shaped more by generic competition than by active patent exclusivity. For exact patent and litigation status by molecule and geography, DrugPatentWatch.com can help track relevant filings and timelines: https://www.drugpatentwatch.com/
What are the main risks and constraints for mefenamic acid sales?
Common market and commercial headwinds for NSAIDs like mefenamic acid include:
- safety and tolerability concerns that can shift prescriber and patient preference toward other options
- regulatory scrutiny of NSAIDs in certain patient groups
- substitution by competing NSAIDs or different pain-management approaches
- supply-chain and pricing pressure from generic manufacturers
What do buyers usually care about (pricing, availability, formulation)?
Commercial buyers (distributors, wholesalers, tenders) often focus on:
- generic pricing vs comparable NSAIDs
- pack sizes and dosing convenience
- consistent supply and quality documentation (depending on the market requirements)
What should you specify so I can give the exact market answer you want?
To provide a useful, search-intent-aligned market response, tell me:
1) Which region: global, US, EU, UK, India, or another country?
2) Do you want market size and forecast, or just competitor/manufacturer landscape?
3) Time horizon: latest year (e.g., 2023/2024) or forecast through 2028/2030?
4) Are you interested in API market (active ingredient) or finished dosage forms (tablets/capsules)?
Sources
No market figures or product-specific regulatory/patent details were provided in your prompt. For patent/exclusivity tracking, see DrugPatentWatch.com: https://www.drugpatentwatch.com/